Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

- PMLiVE

GSK sets up new research initiative in Seattle

Will use an independent research base to understand how cells work

- PMLiVE

Novartis gets FDA nod for rare blood disorder drug

Promacta will provide a treatment option for children over 6 years old

- PMLiVE

Astellas’ Xtandi cancer drug rejected by NICE

England’s HTA questions the treatment’s efficacy and cost

- PMLiVE

Patient survey finds pharma falls short on drug pricing

The industry is coming under increasing attack from all sides as price tags rise

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

National Institute for Health and Care Excellence NICE logo

Roche, Novartis and Bayer gain NICE recommendations

Comes after the Institute effectively shut down for the General Election

- PMLiVE

Novartis and Google to fund ‘robotic pill’ maker

Firms sign up to Rani Therapeutics’ new drug delivery system

- PMLiVE

New health ministers and re-appointments after reshuffle

Industry sees both continuity and change after the UK’s General Election

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

- PMLiVE

George Freeman re-appointed as UK life science minister

Industry welcomes his continuation in this pharma-focused role

- PMLiVE

Pfizer maintains lead in top CNS drug sales – just

But Biogen is looking to take the top spot next year as its MS portfolio grows

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links